Albany, NY -- (SBWIRE) -- 03/16/2018 -- Personalized therapy is related to the genetic makeup of a person. It helps doctors to understand how a tumor grows in a particular patient to identify effective screening, control, and treatment methods. : Doctors are engaged in developing novel treatments with fewer side effects as compared to the traditional treatments. Doctors perform various genetic tests on cancer cells and on normal cells, to develop new customized treatment according to the patient’s needs.
Before personalized therapy, most patients with a specific stage and type of cancer received similar treatment. However, it is evident that certain treatments work specifically on some patients and give better results, as compare to other patients. Development in the field of genetics has led scientists to identify genetic differences in certain patients and their cancer, this described several other responses to treatment. A cancer patient can obtain a standard treatment strategy, such as tumor removal. The doctors can prescribed a personalized cancer treatment. Personalized therapy is an important part of cancer treatment or a part of the clinical trial. A clinical trial is an investigation study including people.
Request to View Brochure of Report -
Targeted cancer treatment targets specific genes and proteins that allow cancer cells to survive and grow. Research scientists are continuously identifying new targets each year. They develop and test new medicines for these new targets. Targeted therapy is used for lung cancer, kidney cancer, gastrointestinal stromal tumor, colorectal cancer, and breast cancer, among others. For the treatment of cancer by targeted therapy, it is very important to find out whether the tumor has specific target or not, and this can be identify by the testing of the tumor sample.
Therapy that targets definite mutant genes, have been existing for few type of cancers since 2001, and by the several studies researchers determined that which tumors will respond best with which drug. For example, changes in the epidermal growth factor receptor (EGFR) gene that affects the response of patient, suffering with lung cancer when the medicine target the EGFR protein. However, recent studies have indicated the shortcomings of targeted therapy by highlighting that the genetic origins of several cancers are both complex and unclear. An extensive diversity of rare mutations can give rise to any type of cancer and mutations in the similar genetic pathways arise in several types of tumors. Rise in the prevalence of cancer, across the world, growing awareness about existing treatments available in the market, and an increasing directness toward the acceptance of promising innovative treatment procedures are key factor driving The Global Personalized Cancer Therapy Market. The market is also driven by substantial developments in gene sequencing methods and high accuracy in its results.
Request to View ToC of Report -
The global personalized cancer therapy market has been segmented into application, technique, technology, and geography. In terms of technique, the global personalized cancer therapy market has been classified into genomics, proteomics, epigenetics, and metabolomics. Based on technology, the market has been segmented into immunohistochemistry, in situ hybridization (ISH), quantitative PCR, next-generation sequencing, and microarray. In terms of application the global personalized cancer therapy market has been categorized into personalized medicines, biomarker discoveries, diagnostics, prognostics, and research applications. Based on geography, the global personalized cancer therapy market has been segmented into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
Key players operating in the global personalized cancer therapy market include Illumina Inc., QIAGEN N.V., NeoGenomics Laboratories, HTG Molecular Diagnostic, and Genomic Health Inc.
Enquiry for discount on this report -